Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 11/20 | 0.66 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.55 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | IL1B | P01584 | 1/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30550160 | 0.91 | MAP1LC3B (0.59) | MAP1LC3BCRBNBRD4IKZF1TNF | |
| SCHEMBL25376586 | 0.91 | MAP1LC3B (0.59) | MAP1LC3BCRBNBRD4IKZF1TNF | |
| SCHEMBL30891812 | 0.89 | MAP1LC3B (0.55) | MAP1LC3BCRBNBRD4 | |
| SCHEMBL24777871 | 0.88 | CRBN (0.57) | MAP1LC3BCRBNBRD4IKZF1TNF | |
| SCHEMBL28341506 | 0.87 | MAP1LC3B (0.62) | MAP1LC3BCRBNBRD4IKZF1TNF | |
| SCHEMBL30438106 | 0.87 | MAP1LC3B (0.62) | MAP1LC3BCRBNBRD4IKZF1TNF | |
| SCHEMBL30250216 | 0.87 | CRBN (0.58) | MAP1LC3BCRBNBRD4IKZF1TNF | |
| SCHEMBL13621972 | 0.87 | CRBN (0.58) | MAP1LC3BCRBNBRD4IKZF1TNF | |
| SCHEMBL30891792 | 0.85 | MAP1LC3B (0.52) | MAP1LC3BCRBNBRD4DDB1 | |
| SCHEMBL25124028 | 0.85 | CRBN (0.71) | MAP1LC3BCRBNBRD4IKZF1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021457-B2 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2021-06-01 | — | — | US | disclosed |
| US-20200071291-A1 | A CLASS OF ISOINDOLONE-IMIDE RING-1,3-DIONE-2-ENE COMPOUNDS, COMPOSITION AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071291-A1 | A CLASS OF ISOINDOLONE-IMIDE RING-1,3-DIONE-2-ENE COMPOUNDS, COMPOSITION AND USE THEREOF | ATG7, MLST8, BECN1 | MAP1LC3B 17/4885CRBN 846/4885BRD4 1350/4885 |
| US-11021457-B2 | Class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | ATG7, MLST8, BECN1 | MAP1LC3B 14/4885CRBN 978/4885BRD4 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.